When should vasopressin and milrinone be added as second‑line agents in shock, and what are the recommended dosing regimens and indications for each?

Vasopressin and Milrinone in Shock Management

Vasopressin should be added as a second-line agent when norepinephrine reaches 0.1–0.25 µg/kg/min and MAP remains below 65 mmHg, at a fixed dose of 0.03 units/min; milrinone is reserved for septic shock patients with adequate MAP (≥65 mmHg) but persistent tissue hypoperfusion and documented myocardial dysfunction, dosed at 0.375–0.75 µg/kg/min.

Vasopressin: Second-Line Vasopressor Strategy

When to Add Vasopressin

• Add vasopressin at 0.03 units/min when norepinephrine requirements reach 0.1–0.25 µg/kg/min and MAP remains <65 mmHg despite adequate fluid resuscitation (minimum 30 mL/kg crystalloid in first 3 hours). 1, 2

• Vasopressin must always be combined with norepinephrine—never use as monotherapy because it lacks the β-adrenergic cardiac support needed in shock states. 1, 2

• The Surviving Sepsis Campaign recommends vasopressin as the preferred second-line agent over escalating norepinephrine doses, based on its norepinephrine-sparing effect and potential renal benefits. 3

Dosing Regimen and Safety Limits

• Fixed dose: 0.03 units/min (range 0.01–0.03 units/min) with no titration required. 1, 2

• Never exceed 0.03–0.04 units/min except as salvage therapy—higher doses cause cardiac, digital, and splanchnic ischemia without additional hemodynamic benefit. 1, 2

• Vasopressin works through V1a receptor-mediated vasoconstriction independent of adrenergic pathways, remaining effective when catecholamine receptors are down-regulated in septic shock. 1

Physiologic Rationale

• Septic shock depletes endogenous vasopressin stores within hours, creating a relative deficiency; approximately 60% of patients show inadequate vasopressin response even five days after recovery. 1

• Vasopressin preferentially constricts efferent renal arterioles while stimulating nitric oxide production, preserving renal perfusion better than pure α-agonists—this explains superior urine output and creatinine clearance compared to norepinephrine alone. 1

Monitoring Requirements

• Maintain continuous arterial blood pressure monitoring via arterial catheter throughout vasopressin therapy. 1, 2

• Assess for digital ischemia, decreased urine output, rising lactate, or worsening organ dysfunction as signs of excessive vasoconstriction. 1

Milrinone: Inotropic Support for Persistent Hypoperfusion

Indications for Milrinone

• Milrinone is indicated when MAP is adequate (≥65 mmHg) with norepinephrine ± vasopressin, but signs of tissue hypoperfusion persist (elevated lactate, urine output <0.5 mL/kg/h, altered mental status, cold extremities) AND documented myocardial dysfunction is present. 4

• The 2025 randomized controlled trial demonstrated that milrinone significantly improved cardiac output at 6 hours (median increase 0.62 L/min vs 0.13 L/min with placebo, p=0.043) in septic shock patients with persistent hypoperfusion. 4

Dosing Protocol

• Loading dose: 25–50 µg/kg over 10–20 minutes (optional, often omitted in shock to avoid hypotension)

• Maintenance infusion: 0.375–0.75 µg/kg/min (equivalent to approximately 2.5–5 µg/kg/min when converted to standard inotrope dosing). 4

• Start at the lower end of the range and titrate based on cardiac output response and blood pressure tolerance.

Critical Distinctions from Dobutamine

• Milrinone is a phosphodiesterase-3 inhibitor that increases cardiac contractility and causes vasodilation through a non-adrenergic mechanism, making it effective when β-receptors are down-regulated. 4

• Unlike dobutamine (which increases myocardial oxygen consumption and frequently causes tachyarrhythmias), milrinone provides inotropic support with less chronotropic effect and may be better tolerated in patients already receiving high-dose catecholamines. 1, 4

Safety Considerations

• Milrinone causes vasodilation—ensure MAP is stable at ≥65 mmHg before initiation, as it may require increased vasopressor support. 4

• The 2025 trial showed no significant difference in complication rates between milrinone and placebo groups, with equivalent 28-day mortality (50% in both groups). 4

• Discontinue milrinone when cardiac output normalizes or if hypotension worsens, as continued infusion may exacerbate vasodilation and increase arrhythmia risk when combined with high-dose catecholamines. 1

Algorithmic Approach to Escalation

Step 1: Initial Resuscitation

• Administer ≥30 mL/kg crystalloid within 3 hours. 1, 2
• Start norepinephrine at 0.02–0.05 µg/kg/min, targeting MAP ≥65 mmHg. 1, 2
• Place arterial catheter for continuous monitoring. 1, 2

Step 2: Persistent Hypotension (MAP <65 mmHg)

• When norepinephrine reaches 0.1–0.25 µg/kg/min, add vasopressin 0.03 units/min. 1, 2
• If MAP remains inadequate, consider epinephrine 0.05–0.3 µg/kg/min as third-line agent. 1, 2

Step 3: Adequate MAP but Persistent Hypoperfusion

• Assess for myocardial dysfunction with bedside echocardiography. 1
• If low cardiac output with elevated filling pressures is documented, add milrinone 0.375–0.75 µg/kg/min. 4
• Monitor lactate clearance every 2–4 hours, urine output ≥0.5 mL/kg/h, mental status, and capillary refill. 1, 2

Step 4: Refractory Shock

• If hypotension persists after ≥4 hours of high-dose vasopressors, add hydrocortisone 200 mg/day IV. 1, 2

Common Pitfalls to Avoid

• Do not delay vasopressin addition while escalating norepinephrine to very high doses—early vasopressin (at norepinephrine 0.1–0.25 µg/kg/min) is associated with lower mortality in observational studies. 5, 6

• Do not use milrinone when MAP is inadequate—its vasodilatory effects will worsen hypotension; ensure MAP ≥65 mmHg first. 4

• Do not exceed vasopressin 0.03–0.04 units/min—the dose-response curve plateaus, and higher doses only increase ischemic complications. 1, 2

• Do not confuse milrinone with dobutamine indications—while both are inotropes, milrinone may be preferred when β-receptor down-regulation is suspected or when dobutamine has caused excessive tachycardia. 4

• Do not focus solely on MAP—tissue perfusion markers (lactate, urine output, mental status) must guide the decision to add inotropic support. 1, 2